These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32124443)

  • 1. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy.
    Chari A; Vogl DT; Jagannath S; Jasielec J; Unger TJ; DeCastro A; Shah J; Kauffman M; Shacham S; Jakubowiak A
    Br J Haematol; 2020 May; 189(4):e126-e130. PubMed ID: 32124443
    [No Abstract]   [Full Text] [Related]  

  • 2. Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
    Magen H; Geva M; Volchik Y; Avigdor A; Nagler A
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e947-e955. PubMed ID: 32868229
    [No Abstract]   [Full Text] [Related]  

  • 3. Importance of quality of life in early phase clinical trials: A case study of selinexor in multiple myeloma.
    Chakraborty R; Efficace F
    Br J Haematol; 2020 May; 189(3):e112-e113. PubMed ID: 32080829
    [No Abstract]   [Full Text] [Related]  

  • 4. Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
    Mouhieddine TH; Parekh S; Cho HJ; Richter J; DeCastro A; Shah J; Landesman Y; Chari A; Jagannath S; Madduri D
    Ann Hematol; 2021 Dec; 100(12):3057-3060. PubMed ID: 33009581
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
    Salcedo M; Lendvai N; Mastey D; Schlossman J; Hultcrantz M; Korde N; Mailankody S; Lesokhin A; Hassoun H; Smith E; Shah U; Diab V; Werner K; Landau H; Lahoud O; Drullinsky P; Shah G; Chung D; Scordo M; Giralt S; Landgren O
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):198-200. PubMed ID: 32001193
    [No Abstract]   [Full Text] [Related]  

  • 6. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.
    Richard S; Richter J; Jagannath S
    Future Oncol; 2020 Jul; 16(19):1331-1350. PubMed ID: 32511022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.
    Mikhael J; Noonan KR; Faiman B; Gleason C; Nooka AK; Costa LJ; Jagannath S; Richardson PG; Siegel D; Chari A; Lentzch S
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):351-357. PubMed ID: 32245742
    [No Abstract]   [Full Text] [Related]  

  • 9. Selinexor: First Global Approval.
    Syed YY
    Drugs; 2019 Sep; 79(13):1485-1494. PubMed ID: 31429063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New European approval: Selinexor for triple class refractory multiple myeloma].
    Nsiala L; Chalopin T
    Bull Cancer; 2022 Jan; 109(1):6-7. PubMed ID: 34857363
    [No Abstract]   [Full Text] [Related]  

  • 11. Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
    Sanchez L; Leleu X; Beaumont JL; Yu H; Hudgens S; Simonova M; Auner HW; Quach H; Delimpasi S; Špička I; Pour L; Kriachok I; Dimopoulos MA; Usenko G; Hájek R; Benjamin R; Sinha DK; Venner C; Illmer T; Garg MK; Stevens DA; Jagannath S; Levy M; Anderson LD; Bahlis NJ; Facon T; Cavo M; Chai Y; Ma X; Tang S; Leong H; Shah J; Shacham S; Kauffman M; Richardson P; Grosicki S
    Am J Hematol; 2021 Oct; 96(10):E383-E386. PubMed ID: 34161627
    [No Abstract]   [Full Text] [Related]  

  • 12. Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas.
    Goldsmith SR; Liu L; Shiah K
    Curr Opin Oncol; 2022 Sep; 34(5):524-530. PubMed ID: 35880450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
    Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
    J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
    Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
    J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis.
    Hughes DM; DeMari S; Hassan H; Sanchorawala V; Sloan JM
    Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):e460-e463. PubMed ID: 33716055
    [No Abstract]   [Full Text] [Related]  

  • 17. Selinexor for the treatment of multiple myeloma.
    Podar K; Shah J; Chari A; Richardson PG; Jagannath S
    Expert Opin Pharmacother; 2020 Mar; 21(4):399-408. PubMed ID: 31957504
    [No Abstract]   [Full Text] [Related]  

  • 18. Selinexor for the treatment of patients with previously treated multiple myeloma.
    Mo CC; Jagannath S; Chari A; Nooka AK; Lonial S; Siegel D; Biran N; Gasparetto C; Bahlis NJ; Richardson P
    Expert Rev Hematol; 2021 Aug; 14(8):697-706. PubMed ID: 33985401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor.
    Gordan LN; Ray D; Ijioma SC; Dranitsaris G; Warner A; Heritage T; Fink M; Wenk D; Chadwick P; Khrystolubova N; Peles S
    Curr Oncol; 2024 Jan; 31(1):501-510. PubMed ID: 38248119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma.
    Ganatra S; Redd R; Hayek SS; Parikh R; Azam T; Yanik GA; Spendley L; Nikiforow S; Jacobson C; Nohria A
    Circulation; 2020 Oct; 142(17):1687-1690. PubMed ID: 33104402
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.